Outset Medical Free Cash Flow 2019-2024 | OM
Outset Medical free cash flow from 2019 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Outset Medical Annual Free Cash Flow | |
|---|---|
| 2023 | -134.81 |
| 2022 | -154.05 |
| 2021 | -133.37 |
| 2020 | -108.09 |
| 2019 | -73.59 |
| 2018 | -48.21 |
| Outset Medical Quarterly Free Cash Flow | |
|---|---|
| 2024-09-30 | -100.68 |
| 2024-06-30 | -79.72 |
| 2024-03-31 | -46.27 |
| 2023-12-31 | -134.81 |
| 2023-09-30 | -109.32 |
| 2023-06-30 | -74.54 |
| 2023-03-31 | -45.57 |
| 2022-12-31 | -154.05 |
| 2022-09-30 | -117.44 |
| 2022-06-30 | -80.39 |
| 2022-03-31 | -39.81 |
| 2021-12-31 | -133.37 |
| 2021-09-30 | -99.85 |
| 2021-06-30 | -71.22 |
| 2021-03-31 | -39.54 |
| 2020-12-31 | -108.09 |
| 2020-09-30 | -79.62 |
| 2020-06-30 | -49.05 |
| 2020-03-31 | -27.69 |
| 2019-12-31 | |
| 2019-09-30 | -57.86 |
| 2018-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.043B | $0.130B |
| Outset Medical Inc. is a medical technology company. Its Tablo(R) Hemodialysis System represents technological advancement enabling novel, transformational dialysis care in acute and home settings. Outset Medical Inc. is based in CA, United States. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $37.870B | 55.80 |
| Tempus AI (TEM) | United States | $9.036B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $8.145B | 207.11 |
| Inspire Medical Systems (INSP) | United States | $5.799B | 180.84 |
| IRhythm Technologies (IRTC) | United States | $3.407B | 0.00 |
| Privia Health (PRVA) | United States | $2.742B | 228.50 |
| Enovis (ENOV) | United States | $2.671B | 17.80 |
| Azenta (AZTA) | United States | $2.470B | 131.83 |
| Clover Health Investments (CLOV) | United States | $2.200B | 0.00 |
| Omnicell (OMCL) | United States | $2.084B | 68.17 |
| Schrodinger (SDGR) | United States | $1.827B | 0.00 |
| 10x Genomics (TXG) | United States | $1.816B | 0.00 |
| Phreesia (PHR) | United States | $1.654B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.850B | 0.00 |
| Standard BioTools (LAB) | United States | $0.577B | 0.00 |
| Talkspace (TALK) | United States | $0.524B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.509B | 0.00 |
| TruBridge (TBRG) | United States | $0.370B | 107.91 |
| Nyxoah SA (NYXH) | Belgium | $0.368B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.343B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.229B | 0.00 |
| Pulmonx (LUNG) | United States | $0.224B | 0.00 |
| American Well (AMWL) | United States | $0.165B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.090B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.087B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.064B | 0.00 |
| CareCloud (CCLD) | United States | $0.056B | 0.00 |
| 111 (YI) | China | $0.050B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.047B | 0.00 |
| Zepp Health (ZEPP) | China | $0.042B | 0.00 |
| Zhongchao (ZCMD) | China | $0.035B | 0.00 |
| Movano (MOVE) | United States | $0.035B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.020B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.020B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.012B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |